GHRS (GH Research PLC) stock: $27.97, $1.92B market cap, $357.5M cash, $1.56B EV, $1.74B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$27.97
Market cap
$1,917.5M
Cash
$357.5M
Enterprise value
$1,560.0M
Balance sheet
Cash
$357.5M
Debt
$0.0M
Net cash
$357.5M
Enterprise value
$1,560.0M
Basic shares
68.6M shares
Fully diluted shares
62.0M shares
Fully diluted market cap
$1,735.0M
Cash per share
$5.21
Cash figures as of 2026-05-14. Database snapshot: 2026-09-22.
Price history
Loading GHRS daily closes…
Loading price history…
Pipeline assets
GH001
Stage not disclosed · Active
Target serotonin receptor
Indications
Initial and additional indications (not named in excerpts)(Stage not disclosed)
Status note Lead candidate; delivered via proprietary aerosol delivery device; excerpts state no clinical stage or indications.
GH002
Stage not disclosed · Active
Target serotonin receptor
Indications
Initial and additional indications (not named in excerpts)(Stage not disclosed)
Status note Second candidate; excerpts state no clinical stage, modality or indications.
Per-asset detail extracted from the 20-F filed 2026-03-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
RTW Investments
5,933,815
no change
1.36%
2026-08-14
Braidwell LP
207,240
+207,240
0.21%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.